NEW YORK , Aug. 13, 2024 /PRNewswire/ -- The global blood glucose monitoring devices market size is estimated to grow by USD 8.70 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 9.45% during the forecast period. Rising global burden of diabetes is driving market growth, with a trend towards smart watch-based apps.
However, stringent regulatory framework poses a challenge. Key market players include Abbott Laboratories, Ascensia Diabetes Care Holdings AG, Bigfoot Biomedical Inc., Dexcom Inc.
, DiaMonTech AG, F. Hoffmann La Roche Ltd., GlySens Inc.
, Health Arx Technologies Pvt. Ltd., Insulet Corp.
, Level2 Medical Services P.A., Levels Health Inc.
, Medtronic Plc, Medtrum Technologies Inc., Novo Nordisk AS, PKvitality S.A.
S., Sanofi SA, Senseonics Holdings Inc., SFC Fluidics Inc.
, Teladoc Health Inc., and Ypsomed Holding AG. Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report Forecast period 2024-2028 Base Year 2023 Historic Data 2018 - 2022 Segment Covered End-user (Hospitals, Home care, and Diagnostic centers), Product (SMBG, CGM, and Lancets), and Geography (North America, Europe, Asia, and Rest of World (ROW)) Region Covered North America, Europe, Asia, and Rest of World (ROW) Key companies profiled Abbott Laboratories, Ascensia Diabetes Care Holdings AG, Bigfoot Biomedical Inc.
, Dexcom Inc., DiaMonTech AG, F. Hoffmann La Roche Ltd.
, GlySens Inc., Health Arx .